Higher Graft CD8 Dose Predicts Better Survival in Hematologic Malignancies

Share this content:
Higher graft CD8 dose predicted better survival in in adults with hematologic malignancies.
Higher graft CD8 dose predicted better survival in in adults with hematologic malignancies.

Higher graft CD8 dose predicted better survival in patients undergoing reduced-intensity conditioned (RIC) allogenic hematopoietic stem-cell transplantation (alloHSCT) in adults with hematologic malignancies, a new study published online ahead of print in the Journal of Clinical Oncology has shown.

For the study, researchers evaluated associations between graft T-cell doses and outcomes in 200 patients who underwent RIC alloHSCT with a peripheral blood stem-cell graft.

Results showed that higher CD8 cell doses were associated with a reduced risk for relapse (aHR = 0.43; P=0.009), improved relapse-free survival (aHR = 0.50; P=0.006), and improved overall survival (aHR = 0.57; P = 0.04). Researchers found no significant increase in graft-versus-host disease or nonrelapse mortality.

RELATED: Offspring of Older Fathers Face Higher Hematologic Cancer Risk

The study also demonstrated that donor age was inversely associated with graft CD8 dose, meaning younger donors were more likely to provide a higher CD8 cell dose graft.

Researchers were able to predict graft CD8 content by measuring the proportion of CD8 cells in a screening blood sample from donors.

Reference

  1. Reshef R, Huffman AP, Gao A, et al. High graft CD8 cell dose predicts improved survival and enables better donor selection in allogenic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2015. [Epub ahead of print]. doi: 10.1200/JCO.2014.60.1203.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters